Jean Roy
Overview
Explore the profile of Jean Roy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
697
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castonguay M, Bernard L, Corriveau M, Castonguay A, Quenneville G, Cohen S, et al.
Transfusion
. 2025 Jan;
PMID: 39876551
Background: Cold agglutinin disease (CAD) or syndrome (CAS) can be particularly challenging when autologous stem cell transplant (ASCT) is needed. Standard peripheral blood stem cell (PBSC) collection and manipulation involve...
2.
Tanguay M, Cohen S, Menard I, Meunier M, Delisle J, Roy J, et al.
Hematology
. 2025 Jan;
30(1):2448552.
PMID: 39763113
Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts...
3.
LeBlanc R, Thiant S, Terra R, Ahmad I, Claveau J, Bambace N, et al.
Curr Oncol
. 2024 Nov;
31(11):7258-7274.
PMID: 39590165
Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte...
4.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner C, et al.
Cancer Med
. 2024 Nov;
13(21):e70332.
PMID: 39499045
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods: We explored disease characteristics, treatments, and...
5.
Roy J, Cohen S, Sauvageau G, Ahmad I, Fournier V, Terra R, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):34.e1-34.e14.
PMID: 39419177
Multiple myeloma (MM) remains associated with a poor outcome, particularly in patients with advanced disease and high-risk (HR) cytogenetics. To date, the only curative treatment is allogeneic (allo) hematopoietic cell...
6.
Guerra Ordaz D, Roy J, Ahmad I, Kaouache M, Ramchatesingh B, Whitelaw S, et al.
Front Med (Lausanne)
. 2024 Sep;
11:1457366.
PMID: 39281820
Introduction: The h-index measures researchers' productivity by assessing simultaneously the number of publications and citations. We aimed to assess the factors that could influence h-index for hematologists practicing in academic...
7.
Tessier C, LeBlanc R, Roy J, Trudel S, Cote J, Lalancette M, et al.
Cancer Med
. 2024 Sep;
13(17):e70192.
PMID: 39225552
Background: Plasma cell leukemia (PCL) is a rare monoclonal gammopathy, associated with short survival. Because of its very low incidence, only a few cohorts have been reported and thus, information...
8.
Ratiu C, Dufresne S, Thiant S, Roy J
Curr Oncol
. 2024 May;
31(5):2780-2795.
PMID: 38785492
Epstein-Barr virus-related post-transplantation lymphoproliferative disorder (EBV-PTLD) is a serious complication following hematopoietic stem cell transplantation (HSCT). A pre-emptive strategy using rituximab, which aims to manage patients early at the time...
9.
[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)]
Dubois V, Blandin L, Duclaut M, Duquesne A, Faivre L, Ferru-Clement R, et al.
Bull Cancer
. 2024 Mar;
112(1S):S68-S77.
PMID: 38485627
Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in...
10.
Cohen S, Bambace N, Ahmad I, Roy J, Tang X, Zhang M, et al.
Blood Adv
. 2023 Jul;
7(19):5717-5726.
PMID: 37467030
Cord blood (CB) transplantation is hampered by low cell dose and high nonrelapse mortality (NRM). A phase 1-2 trial of UM171-expanded CB transplants demonstrated safety and favorable preliminary efficacy. The...